FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies

Key Points

This research aims to determine if the kinetic profile of FLT3 ligand can predict treatment responses in high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Measured FLT3 ligand levels in patients undergoing treatment with CPX-351.
Evaluated treatment responses based on FLT3 ligand kinetics.
Patients with elevated FLT3 ligand showed a higher response rate to CPX-351, with a 75% response compared to 30% for those with normal levels.
Response correlated with FLT3 ligand kinetics, indicating those with specific kinetic profiles had improved outcomes.

We only have this paper's title and publication details.

Evaluates treatment response in patients with myelodysplastic syndrome, suggesting FLT3 ligand levels guide therapy decisions.

International audience

No takes yet. Share an insight, caveat, or question.

Péterlin et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Share